EXTX Fair Value & Analysis

Healthcare · NO · Market cap 83.7M NOK

Below-average quality, and screening another 72% overvalued on our models.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits above even our optimistic bull case (kr 0.2700). The favourable scenario is already priced in.
• Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (kr 0.1400 to kr 0.2700) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 24, 2026.

How to read this chart

60‑month range kr 0.6500 – kr 28.60 · fair‑value band kr 0.1400 – kr 0.2700 · the kr 0.7500 price screens above the kr 0.2100 fair value. Dashed = 300-day average. As of Aug 24, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

EXTX (EXTX) currently trades at kr 0.7500, while our model-based Fair Value estimate is kr 0.2100, implying the stock looks roughly 72.0% overvalued today. The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at 59.0K NOK. Fundamentals as of Aug 24, 2026

Our scenario range runs from kr 0.1400 (bear case) to kr 0.2700 (bull case); at kr 0.7500, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 75% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -63% fair-value upside, at -72%, EXTX screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a novel ultrasound-mediated technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT) in Norway.

Full company description

EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a novel ultrasound-mediated technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT) in Norway. The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various applications, including oncology, neurological conditions, and gene therapy. The company's ACT platform is under Phase 2 clinical trial for the treatment of pancreatic disease; Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for glioblastoma, and immunotherapy diseases, as well as CNS diseases and gene therapy. It has a collaboration with GE Healthcare. The company was formerly known as Phoenix Solutions AS. EXACT Therapeutics AS was founded in 2012 and is based in Oslo, Norway.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

EXTX reported revenue of kr 0 in FY2025 versus kr 0 in FY2021. Reported net income was −kr 87.0M in FY2025.

EXTX screens 72% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Peer Group

Biotechnology · 627 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Biotechnology median · lower = cheaper

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 24, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.